Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
Fanconi anemia (FA) is an autosomal recessive disease characterized by progressive bone
marrow failure, variable congenital abnormalities and a predisposition to malignancy,
particularly acute myeloid leukemia (AML) and squamous cell carcinoma (SCC). Improved
transplant outcomes are modifying the natural history of Fanconi Anemia. Improved transplant
survival, no radiation exposure, and almost no GVHD increases the importance of addressing
later SCC even further. The investigators hypothesize that quercetin will prevent or delay
the development of SCC and associated complications, there by ameliorating or delaying the
need for potentially lethal treatment with chemotherapy and/or radiation therapy for the
same.
Funding Source - FDA Office of Orphan Products Development (OOPD)